Hideki Tanzawa

Title: Innovations of Hideki Tanzawa

Introduction

Hideki Tanzawa is a notable inventor based in Chiba, Japan. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of 2 patents, his work focuses on improving the effectiveness of chemotherapy.

Latest Patents

One of his latest patents is a method of determining the administration effect in cancer chemotherapy with S-1. This method allows for a quick, simple, and accurate assessment of the therapeutic effect of the anticancer drug S-1, which consists of three active ingredients: tegafur, gimeracil, and oteracil potassium. The process involves measuring the expression level of a decorin gene in a biological sample from the patient and determining the administration effect based on this measurement.

Another significant patent involves a new cytotoxic protein known as M toxin, which is produced by a specific transformant. This invention provides a cytotoxic protein and an antitumor agent that utilizes this protein, offering new avenues for cancer treatment.

Career Highlights

Hideki Tanzawa has worked with esteemed institutions such as Chiba University and Fourier Inc. His research and innovations have contributed to advancements in cancer therapy, showcasing his dedication to improving patient outcomes.

Collaborations

He has collaborated with notable colleagues, including Atsushi Kasamatsu and Katsuhiro Uzawa, further enhancing the impact of his work in the scientific community.

Conclusion

Hideki Tanzawa's contributions to cancer treatment through his innovative patents highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in chemotherapy and patient care.